Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-2: intermittent versus continuous panitumumab plus FOLFIRI in first-line unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer
2023-509551-14-00Phase 3Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Time to Treatment Failure. Planned start Jun 2024; status: authorised.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2023-509551-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509551-14-00.